Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease

Jonathan Golledge1, 2, 3 and Aaron Drovandi1, 2

1 Queensland Research Centre for Peripheral Vascular Disease, College of Medicine and Dentistry, James Cook University, Townsville, Queensland, Australia
2 The Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland, Australia
3 The Department of Vascular and Endovascular Surgery, The Townsville University Hospital, Townsville, Queensland, Australia

Background

Peripheral artery disease (PAD) has been defined as an atherothrombotic occlusive disease of the lower limb arteries estimated to affect over 220 million people worldwide1). PAD can lead to leg pain brought on by walking, known as intermittent claudication, or in severe cases constant pain in the foot, or ischemic ulcers or gangrene, collectively known as chronic limb-threatening ischemia2). PAD may also be asymptomatic or associated with atypical symptoms such as a burning sensation in the leg3). PAD is associated with poor health-related quality of life4) and a high risk of major adverse cardiovascular events (myocardial infarction, stroke, or cardiovascular death; MACE) and major adverse limb events (peripheral revascularization or major amputation; MALE)5, 6). The risk of adverse events is particularly high for people with chronic limb-threatening ischemia7, 8).

PAD, as diagnosed by ankle-brachial pressure index (ABPI) <0.9, has been estimated to affect nearly 10% of the population worldwide, affecting 6%, 9%, 12%, and 16% of 50-, 60-, 70-, and 80-year-olds, respectively7). Given the aging of the world population, particularly in developed countries, PAD is projected to represent an important cause of morbidity and mortality in the future8). The frequency of adverse events due to PAD is substantial. Recent

Key words: Secondary prevention, Modifiable risk factors, Medical management
series report an incidence of MACE of approximately 25% over 5 years in people referred to hospital with PAD10, 11, with outcomes being particularly poor for people presenting with chronic limb-threatening ischemia, with MACE rates of approximately 10% per year7). Mortality rates of approximately 20% within 5 years of diagnosis have also been reported12. The health service costs of managing PAD-related adverse events have also been deemed significant13, 14. Multiple clinical trials have highlighted that the incidence of MACE is higher in people presenting with PAD than those with some other presentations of cardiovascular disease such as coronary artery or cerebrovascular disease5, 15. This highlights the importance of implementing medical treatments effective at improving outcomes in PAD patients5, 15.

The main strategy to reduce MACE and MALE is the medical management of atherosclerosis risk factors, including appropriate prescription of anti-platelet and anti-thrombotic drugs; control of lipids, blood pressure, and diabetes; and smoking cessation where relevant. However, a growing body of published literature has demonstrated that the implementation of these treatments remains poor due to multiple interrelated issues11, 16-20. Firstly, in many countries, the medical management of people with PAD is managed by a combination of general practitioners and vascular surgeons21, 22, who may have not received specific and up-to-date training on the medical management of atherosclerosis, which has become increasingly complex. Furthermore, published evidence that these health professionals rely on have been limited or have presented conflicting results with regard to safe and appropriate targets16, 17, 23-25. Finally, current international guidelines that include or are focused on PAD do not comprehensively describe how to implement the medical management of PAD, since they aim to cover all aspects of arterial disease diagnosis and management2, 26-28.

There is, therefore, a need for an up-to-date review of the rationales and suggested pathways to implement optimal medical management of PAD. This review focuses on the current evidence from randomized controlled trials (RCTs) and meta-analyses regarding the most appropriate medical management of PAD in order to reduce the risk of MACE and MALE. The review aimed to guide health professionals who manage patients with PAD in identifying relevant risk factors and implementing appropriate medical therapies. Table 1 briefly summarizes the modifiable medical risk factors of importance from each key international guideline, including specific targets and overall medication recommendations where described. The risk factors discussed are as follows: preventing thrombus formation, lowering low-density lipoprotein cholesterol (LDL-c), blood pressure control, blood glucose control, and cessation of tobacco smoking. Failure to control these risk factors has been found to be associated with an increased risk of adverse events. For example, high blood pressure (systolic blood pressure >140) has been associated with increased risk of MACE of 1.23 (95% confidence intervals, CI, 1.00–1.51)11. Diabetes, particularly insulin treated, has been associated with increased mortality among people with PAD (hazard ratio, HR, 2.94, 95% CI 1.86–4.66)16. Prescription of a statin has been associated with a 30% reduction (HR 0.70, 95% CI 0.61–0.82) in the incidence of MALE in a previous systematic review29. Similarly, having no diabetes and the prescription of a statin have been associated with a lower risk of major amputation in people with PAD30. This review does not focus on the management of the leg symptoms of PAD, such as intermittent claudication. Readers are referred to previously published reviews on exercise therapy and revascularization used to treat the leg symptoms of PAD31-33.

1. Anti-Platelet and Anti-Coagulant Treatments

1a. Overall Recommendations

Current international PAD guidelines have strongly recommended the prescription of an anti-platelet medication to people with symptomatic PAD to prevent MACE2, 26-28. The two anti-platelet medications recommended are aspirin (75–325 mg daily) or clopidogrel (75 mg daily). The American, Asia-Pacific and European guidelines recommend either of these drugs27, 28. The global vascular guidelines on the management of chronic limb-threatening ischemia favors the use of clopidogrel2. Recent guidelines recommend low-dose rivaroxaban, in addition to low-dose aspirin, in patients at high risk of events after considering the risk of bleeding.

1b. Summary of Evidence

Several meta-analyses of RCTs have examined the risks and benefits of anti-platelet drugs in people with PAD34-37. A Cochrane meta-analysis showed that an anti-platelet drug compared to placebo, reduced all-cause (relative risk, RR, 0.76, 95% CI 0.60–0.98) and cardiovascular mortality (RR 0.54, 95% CI 0.32–0.93) in patients with intermittent claudication34. A more recent meta-analysis supports clopidogrel as the anti-platelet of choice to limit MACE. The network meta-analysis of 49 RCTs involving 34,518 PAD patients examined the relative benefits of different
| Risk factor                  | Asian Pacific Society of Atherosclerosis and Vascular Diseases<sup>26</sup> | European Society of Cardiology<sup>27</sup> | Global CLTI<sup>2</sup> | American College of Cardiology & American Heart Association<sup>26</sup> |
|-----------------------------|---------------------------------------------------------------------------|---------------------------------|-------------------|------------------------------------------------------------------------|
| Anti-platelet treatments    | Aspirin alone (75-325mg daily) or clopidogrel alone (75mg daily) in patients with symptomatic PAD. | Antiplatelet therapy is recommended in all patients with symptomatic PAD (no specific medications recommended). | Treat all patients with CLTI with an anti-platelet agent; consider clopidogrel as the agent of choice. | Aspirin alone (75-325mg daily) or clopidogrel alone (75mg daily) in patients with symptomatic PAD. Antiplatelet therapy is reasonable in asymptomatic PAD. |
| Anticoagulation treatments  | Aspirin (100mg daily) plus rivaroxaban (2.5mg twice daily) may be considered in symptomatic PAD. | No specific recommendations provided. | Consider low-dose aspirin and rivaroxaban (2.5mg twice daily) in patients with CLTI. | Anticoagulation should not be used in patients with PAD to reduce the risk of cardiovascular ischaemic events. |
| Control of low density lipoprotein | A statin is recommended for all patients with PAD. | Statins are recommended in all patients with PAD. Serum LDL-c should be reduced to < 1.8mmol/L or decreased by ≥ 50% if initial LDL-c level is 1.8-3.5mmol/L. | Use moderate or high intensity statin therapy in patients with CLTI. | A statin medication is indicated for all patients with PAD. |
| Control of blood pressure  | Antihypertensive therapy for patients with PAD and hypertension; ACEI or ARB can reduce cardiovascular ischemic events. | Control blood pressure to < 140/90mmHg in PAD patients with hypertension; ACEI or ARB should be considered first-line. | Control systolic blood pressure to < 140mmHg and diastolic < 90mmHg in patients with CLTI. | Antihypertensive therapy for all patients with hypertension and PAD; ACEI or ARB can reduce the risk of cardiovascular ischaemic events. |
| Control of diabetes        | Management should be coordinated between a healthcare team (no specific medication recommendations). | Strict glycaemic control is recommended in all diabetic patients with PAD (no specific medication recommendations). | Control T2DM in CLTI patients to < 7% HbA1c; use metformin as primary hypoglycaemic agent. | Management should be coordinated between a healthcare team (no specific medication recommendations). |
| Smoking Cessation          | PAD patients who smoke should be advised to quit at every visit; assist in developing a quit plan including pharmacotherapy and/or referral to a smoking cessation program. Patients should avoid exposure to environmental tobacco smoke. | Smoking cessation is recommended for all PAD patients. No specific medications or other interventions provided. | Offer smoking cessation interventions (pharmacotherapy, counselling, or behaviour modification therapy) to all patients with CLTI. Ask smokers and former smokers about status of tobacco use at every visit. | PAD patients who smoke should be advised to quit at every visit; assist in developing a quit plan including pharmacotherapy and/or referral to a smoking cessation program. Patients should avoid exposure to environmental tobacco smoke. |

ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin-2 receptor blocker; CLTI: chronic limb-threatening ischemia; HbA1c: haemoglobin A1c (glycated haemoglobin); LDL-c: low-density lipoprotein-c; PAD: peripheral artery disease; T2DM: type-2 diabetes mellitus
anti-platelets\textsuperscript{35). It was reported that aspirin was not effective at reducing MACE compared to placebo\textsuperscript{35), while clopidogrel did (RR 0.72; 95% CI 0.58–0.91, number needed to treat, NNT, 80). Clopidogrel also showed the most favorable benefit-harm profile (79% cumulative rank probability best and 77% cumulative rank probability safest)\textsuperscript{35). These findings were consistent with an earlier conventional smaller meta-analysis, which reported that aspirin did not significantly reduce MACE but did reduce the risk of nonfatal stroke (RR 0.64, 95% CI 0.42–0.99)\textsuperscript{36). The preference for clopidogrel is also supported by the CAPRIE trial\textsuperscript{37), which reported that from 6,452 patients that had PAD, there was an RR reduction in events of 23.8% (95% CI 8.9, 36.2) in those administered with clopidogrel (75 mg daily) compared to aspirin (325 mg daily)\textsuperscript{35.}

Another consideration is the benefit of anti-platelet medications on the patency of lower limb endovascular or open surgical revascularization performed in people with PAD. In the network meta-analysis discussed above, dual anti-platelet therapy with clopidogrel plus aspirin significantly reduced major amputations following leg revascularization compared to aspirin alone (RR 0.68; 95% CI 0.46, 0.99, NNT 94), though the risk of severe bleeding was determined to be significantly higher (RR 1.48; 95% CI 1.05, 2.10, number needed to harm 215)\textsuperscript{35). This has led to a weak recommendation in current guidelines that dual anti-platelet therapy (clopidogrel and aspirin) may reduce the risk of limb-related events after lower extremity revascularization for up to 6 months\textsuperscript{2, 27, 28).}

There have been few trials of warfarin in people with PAD undergoing peripheral revascularization; overall, these have not provided convincing evidence of benefit, and current guidelines recommend against its use to reduce MACE and MALE in people with PAD\textsuperscript{2, 26-28, 38). Two recent trials have tested the benefit of low-dose rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg daily) in people with PAD\textsuperscript{40, 42). The COMPASS trial tested whether this combination reduced the risk of MACE compared with low-dose aspirin alone\textsuperscript{41). Among 6,391 patients with PAD, the combination significantly reduced the risk of MALE (HR 0.57, 95% CI 0.37, 0.88) and major amputation (HR 0.33, 95% CI 0.12, 0.92), although major bleeding was more common (HR 1.61, 95% CI 1.09, 2.36)\textsuperscript{40). Combination therapy also significantly reduced the risk of MACE compared to aspirin alone, although this was reported for a larger group of vascular disease patients including those with carotid artery disease (HR 0.72, 95% CI 0.57, 0.90)\textsuperscript{42). Meanwhile, the VOYAGER PAD trial tested if the same combination compared with aspirin alone reduced the incidence of acute limb ischemia, major amputation from vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes in 6,564 people recently having peripheral revascularization\textsuperscript{40). People given aspirin and rivaroxaban had a significant reduction in the primary end-point (HR 0.85, 95% CI, 0.76, 0.96), with an increased risk of major bleeding (HR 1.42, 95% CI 1.10, 1.84).

Overall, these trials provide evidence that low-dose rivaroxaban plus low-dose aspirin is superior to aspirin alone in reducing the risk of MACE and MALE among people with PAD, but with increased risk of major bleeding. As a result, recent guidelines have weakly recommended that low-dose rivaroxaban plus low dose-aspirin may be considered to reduce MACE and MALE in people with symptomatic PAD, having considered the associated risk of bleeding\textsuperscript{28). Whether rivaroxaban and aspirin are superior to clopidogrel alone remains undetermined.

### 2. Control of Lipids

#### 2a. Overall Recommendations

Current PAD guidelines strongly recommend the prescription of statin in all PAD patients, although there is a lack of clarity on the exact statin choice and other agent choice if statins are not tolerated or contraindicated\textsuperscript{2, 26-28). Some guidelines focus on LDL-c targets rather than recommending specific agents, as there is no evidence on ezetimibe in PAD and limited but increasing evidence on the effectiveness of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. The recent European Society of Cardiology and European Atherosclerosis Society guidelines suggest people with PAD should receive the maximum tolerated dose of a statin, plus ezetimibe, or a PCSK9 inhibitor\textsuperscript{43). These guidelines also indicate that all people with PAD should be considered at very high risk of MACE; thus, treatment should target a LDL-c < 1.4 mmol/L, which is more intensive than targets recommended in PAD-focused guidelines\textsuperscript{2, 26-28, 43). The likely benefit of LDL-c-lowering treatments, as with other medical management interventions, depends on absolute risk. While all people with PAD have a substantial risk of MACE and MALE, this is particularly high for some groups, such as people with chronic limb-threatening ischemia, or evidence of more severe peripheral ischemia or physical impairment\textsuperscript{2, 7, 44, 46). None of the PAD guidelines provide recommendations for treatments to lower triglycerides.
2b. Summary of Evidence

Two previous RCTs have tested the benefit of treatments to lower LDL-c among people with PAD. The UK Heart Protection Study randomized 6,748 people with PAD or abdominal aortic aneurysm to simvastatin 40 mg or placebo. Simvastatin led to an average lower LDL-c of 1 mmol/L compared to placebo, resulting in a significant reduction in major vascular events (HR 0.78, 95% CI 0.71, 0.85) and peripheral revascularization events, but not amputations. None of the other large statin trials have reported findings restricted to people with PAD.

The FOURIER trial tested the PCSK9 inhibitor evolocumab in 3,642 people with PAD. Evolocumab significantly reduced median LDL-c by about 1.6 mmol/L and the risk of MACE (HR 0.73, 95% CI 0.59, 0.91) and MALE (HR 0.58, 95% CI 0.38, 0.88). No increase in adverse events in participants administered with evolocumab was reported. There is current debate on whether PCSK9 inhibitors are a cost-effective therapy given the significant cost associated with their use. A recent analysis modeled the effect of a PCSK9 inhibitor, using the data from the FOURIER trial, based on the incidence of MACE and MALE among a group of Australian patients with PAD. It was estimated that intensive LDL-c lowering using a PCSK9 inhibitor would lead to an absolute risk reduction in MACE of 6.1% (95% CI 2.0, 9.3, NNT 16) and MALE of 13.1% (95% CI 4.1, 20.5, NNT 8) in people with chronic limb-threatening ischemia compared to 3.2% (95% CI 1.1, 4.8, NNT 32) and 5.3% (1.7, 8.3, NNT 19) in people with intermittent claudication. This illustrates the potential advantage of intensive management in people at highest risk, such as those with chronic limb-threatening ischemia. The JELIS trial reported that people with PAD (n=223) randomized to eicosapentaenoic acid (EPA) had a significant reduction in major coronary events (HR 0.44, 95% CI 0.19, 0.97). The REDUCE-IT trial, which included people with PAD, reported that EPA significantly reduced the risk of MACE (HR 0.74, 95% CI 0.65, 0.83). These findings suggest that there may also be benefit in lowering triglycerides in people with PAD.

3. Control of Blood Pressure

3a. Overall Recommendations

Current PAD guidelines strongly recommend people with PAD who also suffer from hypertension should receive an antihypertensive medication, favoring the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Some guidelines recommend a blood pressure target of less than 140/90 mmHg.

3b. Summary of Evidence

Depending on the definition and study entry criteria, between 38 and 86% of people with PAD have been determined to have hypertension. The HOPE study is the only large trial that has examined whether a medication for hypertension reduces MACE in people with PAD, which included 1,715 people with symptomatic PAD. Randomization to a 2.5 mg dose of ramipril was found to reduce the risk of MACE, in comparison to placebo (HR 0.75, 95% CI 0.61, 0.92). In contrast, the SPRINT trial reported that among a group of 9,361 people with blood pressure ≥130 mmHg, including some participants with PAD, intensive blood pressure lowering aimed to achieve systolic blood pressure ≤120 mmHg significantly reduced vascular events (myocardial infarction, acute coronary syndrome, stroke, heart failure, or cardiovascular death: HR 0.75, 95% CI 0.64, 0.89) and all-cause mortality (HR 0.73, 95% CI 0.60, 0.90). The trial excluded people with diabetes and reported a significantly increased rate of serious adverse events believed to be related to intensive blood pressure lowering. To the best of our knowledge, the trial has not separately reported the results for the participants with PAD. One observational study reported an increased rate of MACE in PAD patients with systolic blood pressure ≤120 mmHg. As a result, further evidence is needed before intensive lowering of blood pressure can be recommended for people with PAD.

4. Control of Diabetes

4a. Overall Recommendations

Most current diabetes treatments have not been tested in RCTs in people with PAD. Current PAD guidelines have emphasized the importance of glucose control in people with diabetes and PAD, although they do not have clear recommendation of how to achieve this. In the absence of clear evidence, it is appropriate to use national and international guidelines for the management of diabetes. These guidelines recommend an algorithm of management to achieve the desired HbA1c target, which is usually <7%.

Metformin is recommended as the first-line treatment unless contraindicated or not tolerated.
Second-line treatments include sodium/glucose cotransport-2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, sulphonylureas, glucagon-like peptide 1 receptor agonists, and insulin.53)

4b. Summary of Evidence

4b. Summary of Evidence

Depending on the study entry criteria and testing, between 14 and 60% of people with PAD have been reported to have diabetes, which is associated with increased mortality.60 Furthermore, poorly controlled diabetes, as estimated by high HbA1c concentrations, has been associated with an increased risk of MACE, MALE, and all-cause mortality in people with PAD.54 59. The ACCORD trial reported that intensive glucose control, as compared to standard glucose control, significantly reduced the risk of lower extremity amputation (HR 0.69, 95% CI 0.48, 0.99) in participants with diabetes.56 These findings emphasize the importance of tight control of diabetes among people with PAD. The novel SGLT-2 inhibitor empagliflozin has recently been reported to improve outcomes among people with diabetes and PAD in a randomized placebo-controlled trial.57 Among the 1,461 participants with PAD and diabetes, empagliflozin was found to reduce the risk of cardiovascular death (HR 0.57, 95% CI 0.37, 0.88) and all-cause mortality (HR 0.62, 95% CI 0.44, 0.88), with no excess of lower limb amputation.57

Meanwhile, the CANVAS trial has reported on the effect of another SGLT2 inhibitor (canagliflozin) in people with diabetes, but it did not specifically report on people with PAD. It was determined that canagliflozin reduced MACE (HR 0.86, 95% CI 0.75, 0.97), but there was also a significant excess of lower limb amputations.57 Whether the latter is a chance or repeatable findings remains unclear, but caution in the use of canagliflozin for people with PAD is currently warranted. As a result, previous lower limb amputation, foot ulcers, and chronic limb-threatening ischemia are currently considered relative contraindications to canagliflozin.

5. Smoking Cessation

5a. Overall Recommendations

Smoking cessation is recommended for all PAD patients, with recommended treatments as follows: counseling, varenicline (a partial nicotine receptor agonist), nicotine replacement therapy, and bupropion (a combined nicotine receptor antagonist and norepinephrine-dopamine reuptake inhibitor).58 60 Recommended counseling approaches include brief advice tailored to the patient’s degree of readiness to quit, use of nonjudgmental communication, motivational interviewing techniques, and intensive behavior counseling.59 60 Guideline-recommended interventions are informed by patient preferences and experiences in quitting.
discussed above are of great potential value. A limited number of clinical trials that have included some participants with PAD have examined the effect of such interventions.

The BRIDGE Cardiovascular Prevention study tested whether a quality improvement intervention could improve the prescription of evidence-based therapies in 1,619 people with cardiovascular disease through a cluster RCT71). The program included case management, audit and feedback, decision support tools based on current guidelines, and distribution of educational materials. Participants in the intervention clusters were more likely to receive a prescription of evidence-based therapies than those in control clusters (odds ratio 2.30; 95% CI 1.14, 4.65) although risk factor control was not significantly improved71).

Another randomized trial tested the benefit of a personalized website along with communication with a nurse practitioner for education among 330 participants with coronary, cerebral, or peripheral atherosclerosis72). After 1 year, the relative reduction in the Framingham risk score was 14% (95% CI 2 to 25%)72). A currently ongoing trial is examining the effect of a nurse-led, person-centered, health-promoting program among 210 people with intermittent claudication that have recently had surgical treatment of intermittent claudication73).

Approaches which have had success in people at risk of cardiovascular disease include practice facilitators74), community health workers 75), online education programs 76), and community forums 76). Another important consideration is whether interventions to improve implementation of medical management should be provided through in-person consultation or can be provided by remote means, such as telehealth. A recent systematic review77) suggests that telehealth can be effective at improving secondary prevention in people with coronary artery disease.

Conclusion

People with PAD have some of the highest adverse event rates among those with cardiovascular disease. Secondary preventive measures for key modifiable risk factors have proven their efficacy, but they remain to be adequately implemented in clinical practice. Thus, effective implementation programs are required to achieve optimal medical management for PAD patients and to reduce adverse events in this patient group.

Acknowledgments

None.
Financial Support

Funding from the National Health and Medical Research Council (1063476 and 1022752), James Cook University, the Townsville Hospital and Health Services Study, Education and Research Trust Fund, and Queensland Government supported this work. JG holds a Practitioner Fellowships from the National Health and Medical Research Council (1117061) and a Senior Clinical Research Fellowship from the Queensland Government, Australia.

Conflict of Interest

The authors declare that they have no conflicts of interest.

References

1) Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UKA, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet, 2013; 382: 1329-1340
2) Conte MS, Bradbury AW, Kolh P, White JV, Dick F, Fritridge R, Mills JL, Ricco JB, Suresh KR, Murad MH; GVG Writing Group. Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. Eur J Vasc Endovasc Surg, 2019; 58: S1-S109
3) McDermott MM, Ferrucci L, Liu K, Guralnik JM, Tian L, Liao Y, Criqui MH. Leg symptom categories and rates of mobility decline in peripheral arterial disease. J Am Geriatr Soc, 2010; 58: 1256-1262
4) Issa SM, Hoeks SE, Scholte op Reimer WJ, Van Gestel AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis D. Health-related quality of life predicts long-term survival in patients with peripheral artery disease. Vasc Med, 2010; 15: 163-169
5) Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation, 2018; 137: 338
6) Cacoub PP, Abola MT, Baumgartner I, Bhatt DL, Creager MA, Liau CS, Goto S, Rother J, Steg PG, Hirsch AT; REACH Registry Investigators. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis, 2009; 204: e86-e92
7) Nastasi DR, Moxon JV, Norman R, Trollope AF, Rowbotham S, Quigley F, Jenkins J, Golledge J. The cost effectiveness of intensive low density lipoprotein-cholesterol lowering in people with peripheral artery disease. J Vasc Surg, 2020
8) Ko T, Higashitani M, Uemura Y, Utsunomiya M, Yamaguchi T, Matsui A, Ozaki S, Tobita K, Kodama T, Morita H, Komuro I. Clinical Outcome and Diverse Risk Factors for Different Therapeutic Target Locations of Peripheral Artery Disease. J Atheroscler Thromb, 2020; 27: 769-779
9) Song P, Rudan D, Zhu Y, Fowkes FJI, Rahimi K, Fowkes FGR, Rudan I. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. Lancet Glob Health, 2019; 7: e1020-e1030
10) Golledge J, Rowbotham S, Velu R, Quigley F, Jenkins J, Bourke M, Bourke B, Thanigaimani S, Chan DC, Watts GF. Association of Serum Lipoprotein (a) With the Requirement for a Peripheral Artery Operation and the Incidence of Major Adverse Cardiovascular Events in People With Peripheral Artery Disease. J Am Heart Assoc, 2020; 9: e015355
11) Thomas Manapurathe D, Moxon JV, Krishna SM, Rowbotham S, Quigley F, Jenkins J, Bourke M, Bourke B, Jones RE, Golledge J. Cohort Study Examining the Association Between Blood Pressure and Cardiovascular Events in Patients With Peripheral Artery Disease. J Am Heart Assoc, 2019; 8: e010748
12) Beckman JA, Jaff MR, Creager MA. The United States preventive services task force recommendation statement on screening for peripheral arterial disease: more harm than benefit? Circulation, 2006; 114: 861-866
13) Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med, 2008; 13: 209-215
14) Malyar N, Fürstenberg T, Wellmann J, Meyborg M, Lüders F, Gebauer K, Bunzemeier H, Roeder N, Reinecke H. Recent trends in morbidity and in-hospital outcomes of in-patients with peripheral arterial disease: a nationwide population-based analysis. Eur Heart J, 2013; 34: 2706-2714
15) Heart Protection Study Collaborative G. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg, 2007; 45: 645-654
16) Golledge J, Quigley F, Velu R, Walker PJ, Moxon JV. Association of impaired fasting glucose, diabetes and their management with the presentation and outcome of peripheral artery disease: a cohort study. Cardiovasc Diabetol, 2014; 13: 147
17) Nastasi DR, Smith JR, Moxon JV, Trollope A, J. G. Prescription of Pharmacotherapy and the Incidence of Stroke in Patients With Symptoms of Peripheral Artery Disease. Stroke, 2018; 49: 2953-2960
18) Reid C, Nelson MR, Shiel L, Chew D, Connor G, DeLooze F. Australians at risk: management of cardiovascular risk factors in the REACH Registry. Heart Lung Circ, 2008; 17: 114-118
19) Haigh KJ, Bingley J, Golledge J, Walker PJ. Barriers to screening and diagnosis of peripheral artery disease by general practitioners. Vasc Med, 2013; 18: 325-330
20) Green FC, Levison R, Newton DJ, Littleford R,
21) Li B, Salata K, de Mestral C, Hussain MA, Aljabri BA, Lindsay TF, Verma S, Al-Omran M. Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update. Ann Vasc Surg, 2019; 58: 166-173

22) Belch J, Topol EJ, Agnelli G, Bertrand M, Califf RM, Clement DL, Creager MA, Easton JD, Gavin JR 3rd, Greenland P, Hankey G, Hanrath P, Hirsch AT, Meyer J, Smith SC, Sullivan F, Weber MA; Prevention of Atherothrombotic Disease Network. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med, 2003; 163: 884-892

23) Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev, 2013; CD003075

24) SPRINT Research Group, Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, Reboussin DM, Rahman M, Opalir S, Lewis CE, Kimmel PL, Johnson KC, Goff DC Jr, Fine LJ, Cutler JA, Cushman WC, Cheung AK, Ambrosius WT. A randomized trial of intensive versus standard blood pressure control. N Engl J Med, 2015; 373: 2103-2116

25) ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 2010; 362: 1575-1585

26) Gerhard-Herman MD, Gornik HL, Barrett C, Barshes NR, Corriere MA, Drachman DE, Fleisher LA, Fowkes FG, Hamburgh NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer FG, Hamburg NM, Kinlay S, Lookstein R, Misra S, Mureebe L, Olin JW, Patel RA, Regensteiner JG, Schanzer FG.
Kantarow S, Kathuria H, Lamphere T, Neptune E, Pacheco MC, Pakhale S, Prezant D, Sachs DPL, Toll B, Upson D, Xiao D, Cruz-Lopes L, Fulone I, Murray RL, O’Brien KK, Pavalangantharajah S, Ross S, Zhang Y, Zhu M, Farber HJ. Initiating Pharmacologic Treatment in Tobacco-Dependent Adults. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med, 2020; 202: e5-e31

Van Schayck OCP, Williams S, Barchilon V, Baxter N, Jawad M, Katsaounou PA, Kirenga BJ, Panaitescu C, Tsiligianni IG, Zwar N, Ostrem A. Treating tobacco dependence: guidance for primary care on life-saving interventions. Position statement of the IPCRG. NPJ Prim Care Respir Med, 2017; 27: 38

NICE. Stop smoking interventions and services: NICE guidelines. In: England PH, editor. 2018

Lu L, Mackay DF, JP, P. Meta-analysis of the association between cigarette smoking and peripheral arterial disease. Heart, 2014; 100: 414-423

Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Bûller HR, MH, P. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg, 2005; 42: 67-74

Jonason T, R. B. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand, 1987; 221: 253-260

Hageman SHJ, de Borst GJ, Dorresteijn JAN, Bots ML, Westerink J, Asselbergs FW, Visseren FLJ; UCC-SMART Study Group. Cardiovascular risk factors and the risk of major adverse limb events in patients with symptomatic cardiovascular disease. Heart, 2020; 10.1136/heartjnl-2019-316088

Armstrong EJ, Wu J, Singh GD, Dawson DL, Pevec WC, Amsterdam EA, Laird JR. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg, 2014; 60: 1565-1571

Katz DA, Hamlin C, Vander Weg MW, Grant KM, Stewart Steffensmeier KR, Paes M, Hawley ST, Gaeth G. Veterans’ preferences for tobacco treatment in primary care: A discrete choice experiment. Patient Educ Couns, 2020; 103: 652-660

Henrikus D, Joseph AM, Lando HA, Duval S, Ukestad L, Kold M, Hirsch AT. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol, 2010; 56: 2105-2112

Rajae S, Holder T, Indes JE, Muhs B, Sarac T, Sumpio B, Toll BA, Ochoa Chaar CI. A Pilot Study of a Standardized Smoking Cessation Intervention for Patients with Vascular Disease. Ann Vasc Surg, 2019; 61: 91-99.e3

Goodney PP, Spangler EL, Newhall K, Brooke BS, Schanzer A, Tan TW, Beck AW, Hallett JH, MacKenzie TA, Edelen MO, Hoel AW, Rigotti NA, Farber A. Feasibility and pilot efficacy of a brief smoking cessation intervention delivered by vascular surgeons in the Vascular Physician Offer and Report (VAPOR) Trial. J Vasc Surg, 2017; 65: 1152-1160.e2

Kehlet M, Heeseman S, Tønnesen H, TV. S. Perioperative smoking cessation in vascular surgery: challenges with a randomized controlled trial. Trials, 2015; 16: 441

Machline-Carrion MJ, Soares RM, Damiani LP, Campos VB, Sampaio B, Fonseca FH, Izar MC, Amodeo C, Pontes-Neto OM, Santos JY, Gomes SPDC, Saraiva JFK, Ramacciotti E, Barros E Silva PGM, Lopes RD, Brandão da Silva N, Guimaraes HP, Piegas L, Stein AT, Berwanger O; BRIDGE Cardiovascular Prevention Investigators. Effect of a Multifacetted Quality Improvement Intervention on the Prescription of Evidence-Based Treatment in Patients at High Cardiovascular Risk in Brazil: The BRIDGE Cardiovascular Prevention Cluster Randomized Clinical Trial. JAMA Cardiol, 2019; 4: 408-417

Vernooij JW, Kaasjager HA, van der Graaf Y, Wiersma J, Grandjean HM, Hovens MM, de Wit GA, Visseren FL; SMARTStudy Group. Internet based vascular risk factor interventions. Position statement of the IPCRG. NPJ Prim Care Respir Med, 2017; 27: 38

Haile S, Linné A, Johansson UB, E, J-A. Follow-up after surgical treatment for intermittent claudication (FASTIC): a study protocol for a multicentre randomised controlled clinical trial. BMC Nurs, 2020; 19: 45

Shelley DR, Gepts T, Simon N, Nguyen AM, Cleland C, Cuthel AM, Rogers ES, Ogedegbe O, Pham-Singer H, Wu W, Berry CA. Cardiovascular Disease Guideline Adherence: An RCT Using Practice Facilitation. Am J Prev Med, 2020; 58: 683-690

Joshi R, Agrawal T, Fathima U, Usha T, Thomas T, Misquith D, Kalantri S, Chidambaram N, Raj T, Singamani A, Hegde S, Xavier D, Devereaux PJ, Pais P, Gupta R, Yusuf S. Cardiovascular risk factor reduction by smoking cessation in vascular surgery: challenges with a randomized controlled trial. BMJ, 2012; 344: e3750

Rich-Edwards JW, Stuart JJ, Skurnik G, Roche AT, Tsigas E, Fitzmaurice GM, Wilkins-Hauge LE, Levkoff SE, Seely EW. Randomized Trial to Reduce Cardiovascular Risk in Women with Recent Preeclampsia. J Womens Health (Larchmt), 2019; 28: 1493-1504

Turan Kavradim S, Özer Z BL. Effectiveness of telehealth interventions as a part of secondary prevention in coronary artery disease: a systematic review and meta-analysis. Scand J Caring Sci, 2020: doi: 10.1111/scs.12785